Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRDIE trial of adjuvant S-1 in vulnerable elderly gastric cancer
jRCTs031180255Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur in gastric cancer (GC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Jan 2017; status: active, not recruiting.
02
Drugs
tegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031180255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180255.